Table 3 Antibody responses in patients vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1
100 μg | 200 μg | ||||||
|---|---|---|---|---|---|---|---|
pt No. | Vaccination cycle | Baseline (dilution titer) | Antibody response (cycle*) | pt No. | Vaccination cycle | Baseline (dilution titer) | Antibody response (cycle*) |
100-01 | 9 | negative | responded(4) | 200-01 | 15 | negative | responded(2) |
100-02 | 3 | negative | no response** | 200-02 | 9 | negative | responded(2) |
100-03 | 3 | negative | no response** | 200-03 | 8 | positive (x1,600) | responded(5) |
100-04 | 7 | negative | no response | 200-04 | 21 | negative | responded(2) |
100-05 | 2 | negative | no response | 200-05 | 3 | negative | responded(2) |
100-06 | 16 | positive (x6,400) | responded(1) | 200-06 | 10 | positive (x400) | responded(1) |
100-07 | 9 | positive (x25,600) | no response | 200-07 | 3 | positive (x25,600) | responded(2)** |
100-08 | 10 | negative | responded(1) | 200-08 | 11 | positive (x400) | responded(1) |
100-09 | 5 | negative | no response | 200-09 | 18 | positive (x400) | responded(3) |
100-10 | 27 | positive (x400) | responded(3) | 200-10 | 11 | positive (x400) | responded(2) |
100-11 | 8 | negative | responded(2) | 200-11 | 3 | positive (x400) | responded(2) |
100-12 | 8 | negative | responded(2) | 200-12 | 9 | negative | responded(1) |
100-13 | 26 | negative | responded(2) | ||||
antibody response rate | 53.8%*** | 100%*** | |||||